AI Insight
A nationwide cross-sectional survey of 38 UK consultant clinicians found substantial variation in how anticoagulation decisions are made for patients with atrial high-rate episodes detected by cardiac implantable electronic devices. The most commonly used threshold for initiating anticoagulation was an episode duration of 24 hours or more, though many clinicians applied lower thresholds or individualised approaches, and nearly half did not factor cumulative AHRE burden into their decisions. Direct oral anticoagulants, particularly apixaban, were universally preferred when anticoagulation was initiated.
Why it matters
This variation in clinical practice reflects the absence of clear, evidence-based guidelines for managing AHRE, which carry an uncertain but real thromboembolic risk. Standardising decision-making thresholds could help reduce both under- and over-treatment in this growing patient population as CIED use continues to increase.
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Background: Atrial high-rate episodes (AHRE) detected by cardiac implantable electronic devices (CIEDs) are associated with increased thromboembolic risk, yet their clinical significance and optimal anticoagulation strategy remain uncertain, particularly in the absence of electrocardiogram (ECG)-confirmed atrial fibrillation. Methods: We conducted a nationwide cross-sectional survey of UK clinicians involved in CIED follow-up. The survey assessed anticoagulation decision-making in AHRE, including episode-duration thresholds, cumulative burden, CHA2DS2-VA use, additional ECG monitoring, and anticoagulant choice. Only responses from UK-based consultant clinicians were included and analysed descriptively. Results: A total of 51 responses were received; 38 met the inclusion criteria and were analysed. Most respondents (86.8%) reported having reviewed AHRE alerts within the preceding six months, indicating that AHRE are commonly encountered in clinical practice. A [≥]24-hour episode was the most common threshold for anticoagulation (44.7%), although many clinicians reported lower thresholds or individualised approaches. Nearly half (44.7%) did not consider cumulative AHRE burden in decision-making. CHA2DS2-VA thresholds also varied, most commonly [≥]2 or [≥]1. Additional ECG monitoring was infrequently performed. Direct oral anticoagulants were universally preferred, with apixaban the most commonly selected agent (73.7%). Conclusion: There is substantial variation in UK clinical practice regarding anticoagulation for AHRE, reflecting ongoing uncertainty and lack of clear guidance. These findings highlight the need for evidence-based thresholds to support consistent and informed clinical decision-making.